干扰素联合新辅助化疗对卵巢上皮性癌合并腹水患者近期疗效的评价  

Evaluation of the clinical effects of interferon combined with neoadjuvant chemotherapy on ovarian cancer complicated with ascites

作　　者：李天人[1] 畅华[1] 郭科军[1] 

机构地区：[1]中国医科大学附属第一医院妇科,辽宁沈阳110001

出　　处：《实用临床医药杂志》2014年第16期171-173,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨干扰素联合TP方案术前新辅助化疗方案在卵巢上皮性癌合并腹水患者治疗中的疗效。方法选取2010年1月—2012年12月本院卵巢上皮性癌合并腹水患者50例,患者均知情同意,行术前新辅助化疗,随机分为2组,其中25例(TPI组)采取多西他赛+卡铂+干扰素方案,25例(TP组)采取多西他赛+卡铂方案,2周期化疗后均行卵巢癌减灭术,比较2组患者临床症状缓解、不良反应、减灭术满意率及术中情况。结果 TPI组新辅助化疗近期有效率为64%,TP组为52%,2组比较差异无统计学意义(P>0.05)。TPI组腹水消退明显优于TP组﹙(P<0.05);卵巢癌减灭术满意率92%高于TP组80%,但差异无统计学意义(P>0.05);手术情况TPI组好于TP组,差异有统计学意义﹙(P<0.05);TPI组患者骨髓抑制及发热不良反应发生率较TP组明显增加,差异有统计学意义(P<0.05),消化道不良反应发生率2组无显著差异﹙(P>0.05)。结论干扰素联合TP方案治疗卵巢上皮性癌合并腹水患者,能更好地缓解临床症状、缩短手术时间并减少术中出血量,但骨髓抑制等不良反应加重。Objective To investigate clinical effects of interferon combined with neoadjuvant chemotherapy on ovarian cancer complicated with ascites. Methods A total of 50 patients with ovarian cancer complicated with ascites admitted in the first hospital of the China Medical University during 2010 to 2012 were analyzed retrospectively. Totally 25 patients were treated by preoperative neoadjuvant chemotherapy with TPI（docetaxel,carboplatin and interferon） regimen,and others received TP（docetaxel and carboplatin） regimen. The resections were taken after 2 cycles of treatment. The remission of the clinical symptoms,side effects of chemotherapy,resection rate of satisfaction and resection situations was analyzed. Results The efficacy rates of TPI and TP regimen were 64% and52% respectively. There was no significant difference between the two groups（P 0. 05）. But the reduction of ascites of TPI regimen was faster. The resection rate of satisfaction was no significant difference between the two groups,while the resection situations of TPI regimen were better. Some of side effects in TP regimen,such as bone marrow suppression,were slighter than TPI regimen. Conclusion Patients with ovarian cancer complicated with ascites could relieve symptoms and resection situations from interferon combined with neoadjuvant chemotherapy,shorten operative time and bleeding,but increase the adverse effects.

关 键 词：卵巢癌 新辅助化疗 干扰素 腹水 

分 类 号：R737.31[医药卫生—肿瘤]